Another study that enrolled patients with different types of tumors, including colon, thyroid and ovarian cancer expressing the BRAF V600 mutation, showed similar results.107 In this study, vemurafenib, an FDA-approved drug against melanoma, was only effective in some of the non-melanoma patients. Here, BRAF is linked to ovarian carcinoma.